24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Actavis
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
14:16
Full list of Israeli high-tech layoffs in 2026
14:13
LinkedIn to shut down Israeli R&D operations and lay off nearly all employees
14:04
China’s AI weather models are challenging the old forecasting order
13:26
OpenAI lets employees cash out $7 billion as IPO plans remain uncertain
More stories
Buzz
Most popular
Daily
Weekly
1
Israeli AI startup Decart nearing $6 billion sale, Musk’s SpaceX circling
2
Israel set to reject $4.2 billion Zim sale despite buyers’ concessions
3
Corma raises $60 million Seed to build AI designed to fight AI-powered cyberattacks
4
Talkspace co-founder Oren Frank dies at 60 after battle with cancer
5
Israel’s Iron Beam laser was hailed as a breakthrough. It still isn’t operational
More news
Actavis
5 stories about Actavis
Allergan Says Teva Bears Sole Liability for Actavis' Actions
02.09.19
|
Hezi Sternlicht
Actavis, which Teva bought from Allergan in 2016 for $40.5 billion, was one of the top U.S. sellers of opioids in 2006-2012
The Crucial Piece of Information Teva Overlooked
24.12.17
|
Sophie Shulman
When Teva went full force after Allergan's generic unit Actavis in what has become the company’s most costly acquisition, generic drug prices were already falling.
Teva Wants to Be Like Mylan: Agile, Lean and Profitable
17.12.17
|
Uri Tal-Tenne
The cost-cutting plan revealed Thursday by Teva CEO Kåre Schultz showcases an intention to transform Teva into a lean and efficient generic drug company, much like main competitor Mylan
Allergan Sketches Road Show to Sell Teva Stake
14.08.17
|
Golan Hazani
The company is in discussions with investment bankers and brokers to sell its Teva shares, said one person familiar with the matter
Allergan Can Now Sell 9.8% Teva Stake
03.08.17
|
Dror Reich
Yesterday, a lock-up period on $3.2 billion worth Teva Pharmaceutical Industries’ shares owned by Allergan ended